Ashland expects modestly lower sales on COVID-19 demand declines

摘要

Ashland says it expects second-quarter sales to fall 10% year on year (YOY), to $574 million, with second-quarter adjusted earnings from continuing operations totaling $51 million, or 84 cents/share. “Strength in many consumer markets was ofset by industrial weakness across the globe,” Ashland says. “Our consumer business units performed particularly well as we experienced signifcantly stronger demand for pharmaceutical excipients, biofunctional ingredients, and additives for hand sanitizers,” says Ashland chairman and CEO Guillermo Novo.